Repetitive Behavior Disorders in People With Severe Mental Retardation

Status Recruiting

Clinical Trial Summary

Repetitive behavior disorders are prevalent among people with severe mental retardation. These disorders can interfere significantly with an individual’s daily functions. This trial is part of a long-term project that has studied the biologic basis of and possible treatments for repetitive behavior disorders. The trial will evaluate the effectiveness of two medications, a selective serotonin reuptake inhibitor (SSRI) and an atypical antipsychotic, in treating repetitive behavior disorders in people with mental retardation.

Clinical Trial Description

Abnormal repetitive behaviors (odd or inappropriate movements, self-injury, and compulsions) are among the aberrant behaviors exhibited by individuals with mental retardation. However, little is known about their pathobiology and treatments are largely unconfirmed by controlled trials. For example, few controlled studies have examined the efficacy of pharmacological treatment of abnormal repetitive behavior in individuals with mental retardation.

This trial is part of a larger project designed to elucidate the neurobiological bases of repetitive behavior disorders and to develop rational, safe, and effective pharmacological treatments. Thus far, the project has established a pathophysiological basis for stereotyped behavior disorder, demonstrated the role of central dopamine deficiency in stereotyped behavior disorder, and provided evidence of the efficacy of both 5-HT uptake inhibitors and atypical antipsychotics in treating stereotyped behaviors.

There is currently little information to guide the clinician in deciding which drug class may be more effective for which abnormal repetitive behaviors and for which individuals. Moreover, little work has attempted to identify variables that may predict differential treatment response. This trial will assess the relative efficacy of an SSRI and an atypical antipsychotic across multiple categories of abnormal repetitive behaviors. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00491478
Study type	Interventional
Source	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contact	Mark Lewis, PhD
Phone	352-392-3471
Email	mlewis@psych.med.ufl.edu
Status	Recruiting
Phase	Phase 3
Start date	September 1992

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02791321` - Fragility Assessment in Adults With ADHD and Mental Retardation	N/A
Recruiting	`NCT01908400` - Safety and Efficacy of BMMNCin Patients With Mental Retardation	Phase 1/Phase 2
Withdrawn	`NCT02245724` - Stem Cell Therapy in Mental Retardation	Phase 1
Completed	`NCT00156221` - MR Scanning of Very Young Children With Severe Developmental Disorders	N/A
Terminated	`NCT02797418` - "Cognitus & Moi": a New Cognitive Remediation Tool	N/A
Completed	`NCT00758108` - Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Completed	`NCT01430845` - Predicting Developmental Disability Type and Mental Retardation Level in Children With General Developmental Delay
Not yet recruiting	`NCT02214745` - Demographic Characteristics of Children Suffering From Mental Retardation or Cerebral Palsy in the Israeli Arab Community	N/A
Active, not recruiting	`NCT00552526` - Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy	Phase 4
Completed	`NCT02943304` - Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
Completed	`NCT00491894` - Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions	Phase 3
Completed	`NCT01291238` - School Intervention With Daily Physical Activity and Healthy Food for Students With an Intellectual Disability.	N/A
Completed	`NCT01456910` - Resistance Training Program, Labor Inclusion, Intellectual Disability	N/A
Completed	`NCT00065273` - Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay	Phase 3
Active, not recruiting	`NCT00065936` - Self-Injury: Diagnosis and Treatment	Phase 3
Completed	`NCT00506259` - Treatment Strategies for Children With Smith-Magenis Syndrome	Phase 1
Not yet recruiting	`NCT05442229` - A Cross-sectional Study to Evaluate Speech and Language Development in Chinese Children Aged 2-6 Years
Active, not recruiting	`NCT06370793` - Ningbo Severe Mental Disorders Cohort
Completed	`NCT01517048` - Brain-Derived Neurotrophic Factor in Obesity and Brain Function
Completed	`NCT03847753` - Exploring the Comorbidity Between Mental Disorders and General Medical Conditions

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.